HAE
Haemonetics Corp.

634
Mkt Cap
$3.28B
Volume
1.21M
52W High
$87.32
52W Low
$47.32
PE Ratio
20.45
HAE Fundamentals
Price
$70.02
Prev Close
$70.11
Open
$69.80
50D MA
$78.94
Beta
0.69
Avg. Volume
726,049.45
EPS (Annual)
$3.31
P/B
3.86
Rev/Employee
$450,156.80
Loading...
Loading...
News
all
press releases
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·7h ago
News Placeholder
More News
News Placeholder
Mizuho Markets Americas LLC Has $6.45 Million Stake in Haemonetics Corporation $HAE
Mizuho Markets Americas LLC cut its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 43.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC...
MarketBeat·3d ago
News Placeholder
Schwartz Investment Counsel Inc. Has $6.69 Million Stock Holdings in Haemonetics Corporation $HAE
Schwartz Investment Counsel Inc. trimmed its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 63.2% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
Haemonetics (NYSE:HAE) Shares Gap Down - Here's What Happened
Haemonetics (NYSE:HAE) Shares Gap Down - What's Next...
MarketBeat·7d ago
News Placeholder
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Zacks·7d ago
News Placeholder
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·10d ago
News Placeholder
Where Haemonetics Stands With Analysts
read more...
Benzinga·10d ago
News Placeholder
Barrington Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock
Barrington Research raised their price target on Haemonetics from $90.00 to $93.00 and gave the company an "outperform" rating in a report on Monday...
MarketBeat·10d ago
News Placeholder
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·13d ago
News Placeholder
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·16d ago
<
1
2
...
>

Latest HAE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.